Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma
Status:
Completed
Trial end date:
2012-03-23
Target enrollment:
Participant gender:
Summary
The purpose of this study is to show whether mepolizumab given every 4 weeks intravenously
(i.v.) can reduce the frequency of asthma exacerbations in subjects with severe asthma
despite receiving high doses of standard asthma medications. The study will look at different
doses of mepolizumab in comparison to a placebo.